Tbp fair value as of yesterday is 1.03 (Morning star report)
CIBC Tetra Bio Pharma Inc TBP QQQQ 18 Apr 2018 02:00 UTC Last Close Fair ValueQ Market Cap Sector Industry Country of Domicile 18 Apr 2018 18 Apr 2018 02:00 UTC 18 Apr 2018 0.73 1.03 111.7 Mil dHealthcare Biotechnology CAN Canada There is no one analyst in which a Quantitative Fair Value Estimate and Quantitative Star Rating are attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, visit https://global.morningstar.com/equitydisclosures Company Profile Tetra Bio Pharma Inc is a multi-subsidiary publicly traded company. It is engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements. Quantitative Scores Scores All Rel Sector Rel Country Quantitative Moat None 41 43 40 Valuation Undervalued 94 86 90 Quantitative Uncertainty Extreme 7 15 19 Financial Health Moderate 46 26 40 Source: Morningstar Equity Research CAN d TBP Undervalued Fairly Valued Overvalued Valuation Current 5-Yr Avg Sector Median Country Median Price/Quant Fair Value 0.71 0.85 0.90 0.83 Price/Earnings 28.3 14.5 Forward P/E 12.4 13.5 Price/Cash Flow 18.6 8.9 Price/Free Cash Flow 25.2 15.9 Trailing Dividend Yield % 1.37 3.44 Price/Book 10.1 30.4 3.6 1.9 Price/Sales 4.1 2.4 Profitability Current 5-Yr Avg Sector Median Country Median Return on Equity % -98.7 12.6 11.5 Return on Assets % -97.8 -325.1 6.3 4.9 Revenue/Employee (K) 306.6 401.7 Financial Health Current 5-Yr Avg Sector Median Country Median Distance to Default 0.5 0.5 0.6 0.5 Solvency Score 498.5 554.8 Assets/Equity 1.0 0.9 1.4 1.2 Long-Term Debt/Equity 0.1 0.2 Price vs. Quantitative Fair Value 2 4 6 8 10 2014 2015 2016 2017 2018 2019 Quantitative Fair Value Estimate Total Return Sales/Share Forecast Range Forcasted Price Dividend Split Momentum: Standard Deviation: 288.13 Liquidity: High 0.59 52-Wk 1.75 0.01 5-Yr 1.75 150.0 -20.0 358.3 285.5 -31.1 Total Return % 153.5 -16.5 352.2 259.3 -32.7 +/ Market (Morningstar World Index) Trailing Dividend Yield % Forward Dividend Yield % -0.9 -3.0 -27.5 -21.2 -12.2 Price/Earnings Price/Revenue Morningstar RatingQ Q QQ QQQ QQQQ QQQQQ 2013 2014 2015 2016 2017 TTM Financials (Fiscal Year in K) 0 0 0 0 0 Revenue % Change -156 -310 -634 -1,037 -6,090 -6,090 Operating Income % Change -2,109 -414 -595 -944 -6,225 -6,225 Net Income -144 -233 -217 -942 -3,892 -3,892 Operating Cash Flow -66 -60 -1 -750 -750 Capital Spending -210 -293 -218 -942 -4,642 -4,642 Free Cash Flow % Sales -0.08 -0.02 -0.01 -0.02 -0.06 -0.06 EPS % Change -0.01 -0.01 -0.01 0.00 -0.05 -0.05 Free Cash Flow/Share Dividends/Share 0.08 0.00 0.00 0.00 0.03 0.02 Book Value/Share 26,257 32,770 58,070 85,014 123,754 152,962 Shares Outstanding (K) Profitability -175.3 -217.4 -154.9 -98.7 -98.7 Return on Equity % -174.2 -163.5 -312.4 -116.0 -97.8 -97.8 Return on Assets % Net Margin % Asset Turnover 1.0 1.5 1.1 1.0 1.0 Financial Leverage Gross Margin % Operating Margin % Long-Term Debt 158 223 -230 1,449 11,162 11,162 Total Equity Fixed Asset Turns Growth Per Share 1-Year 3-Year 5-Year 10-Year Revenue % 0.0 0.0 0.0 Operating Income % Earnings % Dividends % Book Value % 429.1 136.8 0.9 Stock Total Return % 12.3 175.3 105.3 Quarterly Revenue & EPS Revenue () Feb May Aug Nov Total 2017 0.0 2016 2015 0.0 0.0 0.0 0.0 2014 0.0 0.0 0.0 0.0 0.0 Earnings Per Share () 2017 -0.01 -0.02 -0.01 -0.02 -0.06 2016 0.00 0.00 0.00 -0.01 -0.02 2015 -0.01 0.00 0.00 0.00 -0.01 2014 0.00 0.00 0.00 -0.01 -0.02 Revenue Growth Year On Year % 2015 2016 2017 Quantitative Equity Report | Release: 18 Apr 2018, 21:20 UTC | Reporting Currency: CAD | Trading Currency: CAD | Exchange:XTSX Morningstar 2018. All Rights Reserved. Unless otherwise provided in a separate agreement, you may use this report only in the country in which its original distributor is based. The information, data, analyses and opinions presented herein do not constitute investment advice; are provided solely for informational purposes and therefore is not an offer to buy or sell a security; are not warranted to be correct, complete or accurate; and are subject to change without notice. Except as otherwise required by law, Morningstar shall not be responsible for any trading decisions, damages or other losses resulting from, or related to, the information, data, analyses or opinions or their use. The information herein may not be reproduced, in any manner without the prior written consent of Morningstar. Please see important disclosures at the end of this report. Page 1 of 4